Sociedad Argentina de Hematología

ISSN 2250-8309


Declaración de Conflictos de Interés

Cesión de Derechos de Autor

Se solicita enviar ambos formularios a:




Revista Argentina de Hematología


Volumen:    21    # Number : 2

Publication Date :    Mayo - Agosto    Year:    2017


Treatment of relapsed/refractory acute myeloid leukemia

Authors: Foncuberta MC, Cranco S

Abstract: Acute myeloid leukemia comprises a group of heterogeneous diseases with distinctive phenotypic and molecular characteristics. Induction chemotherapy is able to reduce tumor burden to a level sufficient to meet the complete remission criteria in the vast majority. However, a significant number of patients do not achieve remission or relapse later, and this is associated with an ominous prognosis. Challenges in the treatment of this population include accurate assessment of disease prognosis through genetic and molecular studies, performance status to assess the ability to tolerate salvage therapies options, choice of chemotherapy schedule most likely to be a success, and accurate identification of suitable patients for hematopoietic stem cell transplantation. Clinicians should consider all currently available approaches, including intensive cytotoxic chemotherapy, new-targeted agents, low intensity treatment and palliative care. Since there is no standard of care in this setting, worldwide recommendation is to enroll patients in an appropriate clinical trial; situation not available to us in most cases.

Key words: Relapsed/refractory acute myeloid leukemia, Salvage therapy, Hematopoietic stem-cell trasplantation, Novel agents.

Pages :

  Resumen             pdf  

Julián Alvarez 146 - Ciudad Autónoma de Bs As - Argentina
(54-11) 4855-2452 / 2485